Clinical Trial Update: Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating fostamatinib alone or with ruxolitinib for myelofibrosis patients with severe thrombocytopenia has been terminated; results were post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Thrombocytopenia

Drugs mentioned

• Fostamatinib (fostamatinib)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Myelofibrosis, Thrombocytopenia | Phase 2 | Status: TERMINATED | Results posted: 2023-12-15